ESR1 and cancer: Estradiol-mediated ER activation induces a stabilization of the DAXX protein, which represses the expression of genes associated with stemness, such as NOTCH4, SOX2, OCT4, NANOG, and ALDH1A; this finding suggests that the combination of endocrine therapy and DAXX-stabilizing agents might represent a potential therapy to inhibit tumor recurrence, through the inhibition of the cancer stem cell activity [394].